Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1988 1
1989 1
1990 2
1991 1
1992 3
1996 3
1997 2
1998 6
1999 5
2000 12
2001 10
2002 8
2003 9
2004 6
2005 5
2006 15
2007 15
2008 9
2009 11
2010 12
2011 12
2012 10
2013 13
2014 9
2015 17
2016 10
2017 15
2018 10
2019 15
2020 22
2021 18
2022 26
2023 16
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

309 results

Results by year

Filters applied: . Clear all
Page 1
An Overview of Glucocorticoid-Induced Osteoporosis.
Ilias I, Milionis C, Zoumakis E. Ilias I, et al. 2022 Mar 19. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2022 Mar 19. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 25905202 Free Books & Documents. Review.
Glucocorticoid (GC)-induced osteoporosis (GCOP) is the most common cause of iatrogenic osteoporosis (OP). ...As some patients on a low GC dose show bone loss at a much higher rate than others on a higher GC dose, genetics may play a role in determining this differen …
Glucocorticoid (GC)-induced osteoporosis (GCOP) is the most common cause of iatrogenic osteoporosis (OP). ...As some patients …
Pathogenic mechanisms of glucocorticoid-induced osteoporosis.
Chen M, Fu W, Xu H, Liu CJ. Chen M, et al. Cytokine Growth Factor Rev. 2023 Apr;70:54-66. doi: 10.1016/j.cytogfr.2023.03.002. Epub 2023 Mar 5. Cytokine Growth Factor Rev. 2023. PMID: 36906448 Free PMC article. Review.
Glucocorticoid (GC) is one of the most prescribed medicines to treat various inflammatory and autoimmune diseases. However, high doses and long-term use of GCs lead to multiple adverse effects, particularly glucocorticoid-induced osteoporosis (GIO). .. …
Glucocorticoid (GC) is one of the most prescribed medicines to treat various inflammatory and autoimmune diseases. However, high doses and l …
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.
Chotiyarnwong P, McCloskey EV. Chotiyarnwong P, et al. Nat Rev Endocrinol. 2020 Aug;16(8):437-447. doi: 10.1038/s41574-020-0341-0. Epub 2020 Apr 14. Nat Rev Endocrinol. 2020. PMID: 32286516 Review.
Glucocorticoids are widely used to suppress inflammation or the immune system. High doses and long-term use of glucocorticoids lead to an important and common iatrogenic complication, glucocorticoid-induced osteoporosis, in a substantial proportion of …
Glucocorticoids are widely used to suppress inflammation or the immune system. High doses and long-term use of glucocorticoids lead t …
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. Buckley L, et al. Arthritis Rheumatol. 2017 Aug;69(8):1521-1537. doi: 10.1002/art.40137. Epub 2017 Jun 6. Arthritis Rheumatol. 2017. PMID: 28585373 Review.
OBJECTIVE: To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). METHODS: We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. ...The …
OBJECTIVE: To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). METHO …
Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.
Laurent MR, Goemaere S, Verroken C, Bergmann P, Body JJ, Bruyère O, Cavalier E, Rozenberg S, Lapauw B, Gielen E. Laurent MR, et al. Front Endocrinol (Lausanne). 2022 Jun 9;13:908727. doi: 10.3389/fendo.2022.908727. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35757436 Free PMC article. Review.
However, both iatrogenic and endogenous glucocorticoid excess are also associated with several side effects including an increased risk of osteoporosis and fractures. Glucocorticoid-induced osteoporosis (GIOP) is a common secondary cause of osteopor …
However, both iatrogenic and endogenous glucocorticoid excess are also associated with several side effects including an increased risk of …
Glucocorticoid-induced Osteoporosis.
Whittier X, Saag KG. Whittier X, et al. Rheum Dis Clin North Am. 2016 Feb;42(1):177-89, x. doi: 10.1016/j.rdc.2015.08.005. Epub 2015 Oct 24. Rheum Dis Clin North Am. 2016. PMID: 26611558 Review.
Glucocorticoid-induced osteoporosis (GIOP) is one of the most common and serious adverse effects associated with glucocorticoid use. This article highlights GIOP pathophysiology, epidemiologic associations, effective treatment, and lifestyle modifications tha …
Glucocorticoid-induced osteoporosis (GIOP) is one of the most common and serious adverse effects associated with glucoc …
Glucocorticoid-induced osteoporosis update.
Adami G, Saag KG. Adami G, et al. Curr Opin Rheumatol. 2019 Jul;31(4):388-393. doi: 10.1097/BOR.0000000000000608. Curr Opin Rheumatol. 2019. PMID: 31045947 Review.
PURPOSE OF REVIEW: Steroid-induced osteoporosis or glucocorticoid-induced osteoporosis (GIOP) is a common form of secondary osteoporosis and is a cause of increased morbidity and mortality. ...SUMMARY: GIOP and fragility fractures are important …
PURPOSE OF REVIEW: Steroid-induced osteoporosis or glucocorticoid-induced osteoporosis (GIOP) is a common form o …
ED-71 Prevents Glucocorticoid-Induced Osteoporosis by Regulating Osteoblast Differentiation via Notch and Wnt/beta-Catenin Pathways.
Rong X, Kou Y, Zhang Y, Yang P, Tang R, Liu H, Li M. Rong X, et al. Drug Des Devel Ther. 2022 Nov 15;16:3929-3946. doi: 10.2147/DDDT.S377001. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36411860 Free PMC article.
PURPOSE: Long-term glucocorticoid- usage can lead to glucocorticoid-induced osteoporosis (GIOP). ...
PURPOSE: Long-term glucocorticoid- usage can lead to glucocorticoid-induced osteoporosis (GIOP). ...
Glucocorticoid-induced osteonecrosis.
Weinstein RS. Weinstein RS. Endocrine. 2012 Apr;41(2):183-90. doi: 10.1007/s12020-011-9580-0. Epub 2011 Dec 15. Endocrine. 2012. PMID: 22169965 Free PMC article. Review.
Awareness of the need for prevention of glucocorticoid-induced fractures is growing, but glucocorticoid administration is often overlooked as the most common cause of nontraumatic osteonecrosis. Glucocorticoid-induced osteonecrosis develops in 9-40% of …
Awareness of the need for prevention of glucocorticoid-induced fractures is growing, but glucocorticoid administration is ofte …
Consensus on diagnosis and management of Cushing's disease: a guideline update.
Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK. Fleseriu M, et al. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. Lancet Diabetes Endocrinol. 2021. PMID: 34687601 Free PMC article. Review.
Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term management to optimise patient outcomes. The Pituitary Society convened a consensus workshop comprising more than 50 academic researchers and clinical experts to discuss the applicati …
Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term management to optimise patient outcomes. Th …
309 results